
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current 0IV3 market cap is 1.97B. The company's latest EPS is USD -0.3391 and P/E is -7.49.
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 460k | 253k | 1.39M | 596k | 237k |
Operating Income | -72.7M | -76.91M | -114M | -138.55M | -193.94M |
Net Income | -68.55M | -75.62M | -116.11M | -141.9M | -184.13M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 165.52M | 270.73M | 226.03M | 190.58M | 394.08M |
Total Liabilities | 30.36M | 59.78M | 99.62M | 110.58M | 146.13M |
Total Equity | 135.16M | 210.95M | 126.42M | 80M | 247.95M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -43.9M | -66.65M | -95.56M | -127.38M | -167.74M |
Investing | 27.4M | -105.32M | 71.95M | 62.07M | -180.32M |
Financing | 19.57M | 168.35M | 48.56M | 87.26M | 362.02M |
Market Cap | 1.97B |
Price to Earnings Ratio | -7.49 |
Price to Sales Ratio | 6.35k |
Price to Cash Ratio | 19.71 |
Price to Book Ratio | 5.56 |
Dividend Yield | - |
Shares Outstanding | 543.06M |
Average Volume (1 week) | 7k |
Average Volume (1 Month) | 6.83k |
52 Week Change | 0.00% |
52 Week High | 3.63 |
52 Week Low | 3.63 |
Spread (Intraday) | 0 (0%) |
Company Name | Geron Corp |
Address |
1209 orange street wilmington, delaware 19801 |
Website | https://www.geron.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions